These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 15310147

  • 1. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
    Park HR, Jung WW, Bertoni F, Bacchini P, Park JH, Kim YW, Park YK.
    Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
    [Abstract] [Full Text] [Related]

  • 2. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K, Oda Y, Sakamoto A, Saito T, Tamiya S, Iwamoto Y, Tsuneyoshi M.
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [Abstract] [Full Text] [Related]

  • 3. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y, Sakamoto A, Satio T, Kawauchi S, Iwamoto Y, Tsuneyoshi M.
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [Abstract] [Full Text] [Related]

  • 4. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors.
    Yokoyama R, Schneider-Stock R, Radig K, Wex T, Roessner A.
    Pathol Res Pract; 1998 Sep; 194(9):615-21. PubMed ID: 9793960
    [Abstract] [Full Text] [Related]

  • 5. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
    Takahashi Y, Oda Y, Kawaguchi K, Tamiya S, Yamamoto H, Suita S, Tsuneyoshi M.
    Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008
    [Abstract] [Full Text] [Related]

  • 6. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
    Miller CW, Aslo A, Won A, Tan M, Lampkin B, Koeffler HP.
    J Cancer Res Clin Oncol; 1996 Jun; 122(9):559-65. PubMed ID: 8781571
    [Abstract] [Full Text] [Related]

  • 7. p53 and ras mutations in Ewing's sarcoma.
    Radig K, Schneider-Stock R, Röse I, Mittler U, Oda Y, Roessner A.
    Pathol Res Pract; 1998 Jun; 194(3):157-62. PubMed ID: 9587933
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
    Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y.
    Cancer Genet Cytogenet; 2000 Jul 15; 120(2):91-8. PubMed ID: 10942797
    [Abstract] [Full Text] [Related]

  • 10. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
    Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M.
    Cancer; 1997 Apr 15; 79(8):1541-7. PubMed ID: 9118036
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. p53 gene mutations in osteosarcomas of low-grade malignancy.
    Radig K, Schneider-Stock R, Haeckel C, Neumann W, Roessner A.
    Hum Pathol; 1998 Nov 15; 29(11):1310-6. PubMed ID: 9824113
    [Abstract] [Full Text] [Related]

  • 13. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
    Dujardin F, Binh MB, Bouvier C, Gomez-Brouchet A, Larousserie F, Muret Ad, Louis-Brennetot C, Aurias A, Coindre JM, Guillou L, Pedeutour F, Duval H, Collin C, de Pinieux G.
    Mod Pathol; 2011 May 15; 24(5):624-37. PubMed ID: 21336260
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Alterations of MDM2 and p53 genes in bone tumors].
    Zhou X, Gao L, Zhe X.
    Zhonghua Bing Li Xue Za Zhi; 1997 Oct 15; 26(5):270-2. PubMed ID: 10374333
    [Abstract] [Full Text] [Related]

  • 16. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
    Hisaoka M, Okamoto S, Morimitsu Y, Tsuji S, Hashimoto H.
    Virchows Arch; 1998 Oct 15; 433(4):323-9. PubMed ID: 9808434
    [Abstract] [Full Text] [Related]

  • 17. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
    Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, Shibata T.
    Am J Surg Pathol; 2012 Mar 15; 36(3):423-31. PubMed ID: 22301501
    [Abstract] [Full Text] [Related]

  • 18. Status of the p53, Rb and MDM2 genes in canine osteosarcoma.
    Mendoza S, Konishi T, Dernell WS, Withrow SJ, Miller CW.
    Anticancer Res; 1998 Mar 15; 18(6A):4449-53. PubMed ID: 9891508
    [Abstract] [Full Text] [Related]

  • 19. COPS3 amplification and clinical outcome in osteosarcoma.
    Yan T, Wunder JS, Gokgoz N, Gill M, Eskandarian S, Parkes RK, Bull SB, Bell RS, Andrulis IL.
    Cancer; 2007 May 01; 109(9):1870-6. PubMed ID: 17366602
    [Abstract] [Full Text] [Related]

  • 20. [Detection of p53 and MDM2 gene expression in osteosarcoma with biotin-labelled in situ].
    Wang X, Wang S, Feng C.
    Zhonghua Wai Ke Za Zhi; 1997 Mar 01; 35(3):178-80. PubMed ID: 10374529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.